Investigation of Naltrexone for Pathological Gambling

Conditions

Pathological Gambling

What is the purpose of this trial?

The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as usual.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Center for Responsible Gaming
Yale University
Dates:
February 2009
Last Updated:
January 29, 2013
Study HIC#:
0901004667

Clinicaltrials.gov ID: NCT01057862